P873: CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS

P873: CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS

Bibliographic Details
Main Authors:	A. Schneller, A. Bolomsky, N. Zojer, M. Schreder, H. Ludwig
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000846372.94975.27

Similar Items

P864: CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA - SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION
by: C. Pfeiffer, et al.
Published: (2022-06-01)

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)
by: H. Ludwig, et al.
Published: (2023-05-01)

Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment
by: Arnold Bolomsky, et al.
Published: (2016-03-01)

Carfilzomib Promotes the Unfolded Protein Response and Apoptosis in Cetuximab-Resistant Colorectal Cancer
by: Ahmad Zulkifli, et al.
Published: (2021-07-01)

Phylogenetic analysis of the MCL1 BH3 binding groove and rBH3 sequence motifs in the p53 and INK4 protein families.
by: Anna McGriff, et al.
Published: (2023-01-01)

Carfilzomib induced Alveolar Hemorrhage
by: Zachary Holtzapple, et al.
Published: (2023-12-01)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
by: H. Quach, et al.
Published: (2022-06-01)

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysisResearch in context
by: Heinz Ludwig, et al.
Published: (2023-04-01)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
by: Pieter Sonneveld, et al.
Published: (2022-10-01)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
by: Anna Astarita, et al.
Published: (2023-02-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

31,873 pelajar daftar masuk 10 universiti
by: Berita, Harian
Published: (2014)

MiR-873-5p: A Potential Molecular Marker for Cancer Diagnosis and Prognosis
by: Yuhao Zou, et al.
Published: (2021-10-01)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
by: Carol Chen-Scarabelli, et al.
Published: (2017-07-01)

Mechanical Properties and Microstructural Evolution of T23 Heat-resistant Steel during Aging at 873K
by: Wang, Lili, et al.
Published: (2008-02-01)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
by: Simone Claudiani, et al.
Published: (2021-09-01)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
by: Ioanna Barla, et al.
Published: (2022-11-01)

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS
by: Ecenur Guder Arslan, et al.
Published: (2023-10-01)

The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
by: Hamada A. Mokhlis, et al.
Published: (2019-03-01)

Deregulation in Japanese gas industries : significance and problems of gas rate deregulation for large industrial customers
by: Inoue, Masayuki
Published: (2009)

Prediction of the creep behavior of P91 Steel at 873 K using continuum damage mechanics model
by: Ferdous, I. U., et al.
Published: (2022)

miR-873a-5p Targets A20 to Facilitate Morphine Tolerance in Mice
by: Jiangju Huang, et al.
Published: (2019-04-01)

P857: BORTEZOMIB- AND CARFILZOMIB-RESISTANT MYELOMA CELLS SHOW INCREASED ACTIVITY OF ALL THREE ARMS OF UNFOLDED PROTEIN RESPONSE AND ENRICHMENT OF SIRTUIN SIGNALING PATHWAY
by: T. Kubicki, et al.
Published: (2022-06-01)

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
by: I. Vaxman, et al.
Published: (2022-06-01)

Carfilzomib and Paclitaxel Co-Loaded Protein Nanoparticles an Effective Therapy Against Pancreatic Adenocarcinomas
by: Cheng WT, et al.
Published: (2021-10-01)

Effect and Significance of BH3-only Protein in Targeted Therapy of Non-small Cell Lung Cancer
by: Weisong GAO, et al.
Published: (2014-11-01)

P955: CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL-LIFE EXPERIENCE OF EMMY
by: C. Hulin, et al.
Published: (2022-06-01)

Effects of thermal aging at 873 K on the impact properties of an ODS ferritic steel
by: M. Oñoro, et al.
Published: (2023-09-01)

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY CO-INHIBITING THE B2 AND B1 PROTEASOME SUBUNITS
by: X. Zhou, et al.
Published: (2023-05-01)

Wetting of liquid aluminum alloys on pure titanium at 873-973 K
by: Peng Jin, et al.
Published: (2019-11-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar D, et al.
Published: (2015-01-01)

The use of carfilzomib to treat extramedullary plasmacytoma and review of the literature
by: Figen Atalay
Published: (2020-01-01)

Real-world effectiveness and safety analysis of carfilzomib–lenalidomide–dexamethasone and carfilzomib–dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis
by: Yoshiyuki Onda, et al.
Published: (2022-06-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Prognostic significance of deregulated dicer expression in breast cancer.
by: Emer Caffrey, et al.
Published: (2013-01-01)

Clinical significance of EPHX2 deregulation in prostate cancer
by: Ming-Sheng Liu, et al.
Published: (2021-01-01)

Melting Behavior and Thermolysis of NaBH4−Mg(BH4)2 and NaBH4−Ca(BH4)2 Composites
by: Morten B. Ley, et al.
Published: (2015-04-01)

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
by: Elyse A. Olesinski, et al.
Published: (2021-06-01)

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
by: Nooka A, et al.
Published: (2013-01-01)